JSR Corporation Acquires Pioneering Cell Line Developer Selexis SA

JSR Corporation, listed on Tokyo Stock Exchange, completed its acquisition of Selexis SA, a pioneering life sciences company and global leader in mammalian cell-line generation technologies on June 21,2017. 

JSR Corporation, through its business unit JSR Life Sciences, provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific. JSR Life Sciences is focused on diagnostics and research products and bioprocessing materials and services for the manufacture of biologics. 

The transaction marks the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.

JSR was represented by Transatlantic Law International (TALI), the London based global innovator in business law services for multinationals in more than 95 countries (www.transatlanticlaw.com), with the legal team led by JSR’s subsidiary, KBI Biopharma General Counsel Rachel Mandell, and the outside legal team led by TALI’s director, Erik D. Lazar and TALI’s Swiss affiliate VISCHER, with Christian Wyss (partner, M&A/life sciences), Gian-Andrea Caprez (managing associate, M&A), Marc Prinz (partner, employment) and Nadia Tarolli (partner, tax) supported by the full VISCHER Swiss M&A team.

“We were delighted with the acquisition and with TALI’s prompt, professional and cost effective service, “ said Ms. Mandell. “The firm’s global M&A capacity and the delivery of results by the Swiss team in a very interesting transaction met all of our expectations.”